Monday, June 01, 2026 11:55:36 AM
CHM 27_28 November 2025 - Final Summary Minutes.pdf
On page 1, DCVax-L was likely the NEW DRUGS LICENSING application for a marketing authorization.
On page 4, there is mention of a glioblastoma treatment attempting to get approval for a NEW CLINICAL TRIAL. You can see it is under the topic of CLINICAL TRIAL APPLICATIONS. This is NOT for DCVax-L. It has NOTHING to do with the MAA decision for the EXISTING & COMPLETED DCVax-L phase 3 clinical trial.
On page 1, DCVax-L was likely the NEW DRUGS LICENSING application for a marketing authorization.
On page 4, there is mention of a glioblastoma treatment attempting to get approval for a NEW CLINICAL TRIAL. You can see it is under the topic of CLINICAL TRIAL APPLICATIONS. This is NOT for DCVax-L. It has NOTHING to do with the MAA decision for the EXISTING & COMPLETED DCVax-L phase 3 clinical trial.
